Kymoral

Simvastatin, the active ingredient in Kymoral, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol and reduces cardiovascular risk in adults with hypercholesterolemia, including those with familial forms of the disorder.

GNH USA supplies Kymoral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets across Europe and other regions. The product meets EU quality standards and is manufactured under strict Good Manufacturing Practice guidelines.

Simvastatin is used to manage disorders of lipid metabolism and to lower cardiovascular risk. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol levels. - Familial hypercholesterolemia: helps achieve target LDL reductions in genetically high cholesterol. - Primary prevention of cardiovascular events: lowers the risk of heart attack and stroke in patients with elevated cholesterol. - Secondary prevention after myocardial infarction: assists in reducing recurrent cardiovascular events.

Simvastatin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea. - Elevated liver enzymes: mild increases in ALT or AST. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of kidney injury. - Hepatotoxicity: significant liver injury with marked enzyme elevation. - Acute renal failure: sudden loss of kidney function. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Myocarditis: inflammation of heart muscle (very rare).

When prescribing Simvastatin, clinicians should consider several precautionary measures to ensure safe use. - Liver function monitoring: obtain baseline and periodic ALT/AST tests. - Muscle symptom assessment: evaluate for unexplained muscle pain, tenderness or weakness. - Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors. - Renal impairment caution: adjust therapy in patients with severe kidney disease. - Pregnancy and lactation: discontinue if pregnancy is confirmed or if breastfeeding. - Store at room temperature: keep tablets in the original container, protect from moisture and heat.

Simvastatin interacts with several medicines that can alter its plasma concentration or increase toxicity risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can cause dangerous increases in simvastatin levels. - Fibrates (gemfibrozil): markedly raise risk of rhabdomyolysis. - Niacin (high‑dose): enhances muscle toxicity. - Antifungal agents (ketoconazole): potentiate statin exposure. - HIV protease inhibitors (ritonavir): significantly increase statin concentrations.

Moderate Interactions (Monitor Closely): - Amiodarone: may increase simvastatin exposure modestly. - Digoxin: monitor for potential increased serum levels. - Warfarin: observe INR for possible changes. - Grapefruit juice: can raise simvastatin levels. - Calcium channel blockers (diltiazem, verapamil): may require dose adjustment.